REFERENCES

1. The World Organization. Hepatits C fact sheet. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-c07.04.202. [Last accessed on 7 Apr 2020].

2. Bartenschlager R, Lohmann V, Penin F. The molecular and structural basis of advanced antiretroviral therapy for hepatits virus C infection. Nat Rev Microbiol 2013;11:482-96.

3. Patin E, Kutalik Z, Guergnon J, Bibert S, Nalps B, et al. Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection. Gastroenterology 2012;143:1244-52.e12.

4. Westbrook RH, Dusheiko G. Natural history of hepatits C. J Hepatol 2014;61:58-68.

5. Nault JC, Mallet M, Pilati C, Calderano J, Bioulac-Sage P, et al. High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun 2013;4:2281.

6. Kao CF, Chen SY, Chen JY, Wu Lee YH. Modulation of 53 transcription regulatory activity and post-translational modification by hepatits C virus core protein. Oncogene 2004;23:2472-83.

7. European Association for the Study of the Liver. EASL recommendation on treatment of hepatits C 2018. J Hepatol 2018;69:461-511.

8. Ghany MG, Morgan TR; AASLD-IDSA Hepatitis C Guidance Panel. Hepatitis C guidance 2019 update: American association for the study of liver diseases-infectious diseases society of america recommendations for testing, managing, and treating hepatitis C virus infection. Hepatology 2020;71:686-721.

9. Butt AS, Sharif F, Abid S. Impact of direct acting antivirals on occurence and reccurence of hepatocellular carcinoma: Biologically plausible or an epiphenomenon? World J Hepatol 2018;10:267-76.

10. Kobzial K, Moser S, Schwarzer R, Laferl H, Al-Zoairy R, et al. Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic responce following interfeon - free direct-acting antiviral treatment. J Hepatol 2016;65:856-8.

11. Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y, et al. Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. Gstroenterology 2017;153:996-1005.e1.

12. Sinagl AG, Lim JK, Knawal F. AGA clinical practice update on interaction between oral direct- acting antivirals for chronic hepatitis C and hepatocellular carcinoma: expert review. Gastoenterology 2019;145:2149-57.

13. Ioannou GN, Feld JJ. What are the benefits of a sustained virologic responce to direct-acting antiviral therapy for hepatitis C virus infection? Gastroenterology 2019;156:446-60.e2.

14. Nagata H, Nakagawa M, Asahina Y, Sato A, Asano Y, et al. Effect of interferon-based and -free therapy on early occurence and recurrence of hepatocellular carcinoma in chronić hepatitis C. J Hepatol 2017;67:933-9.

15. Cabibbo G, Petta S, Calvaruso V, Cacciola I, Cannavo MR, et al. Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study. Aliment Pharmacol Ther 2017;46:688-95.

16. Singal AG, Rich NE, Metha N, Branch A, Pillai A, et al. Direct-acting antiviral therapy not associated with recurrence of hepatocellular carcinoma in a multicenter North American cohort study. Gastroenterology 2019;156:1683-92.e1.